Amgen Inc. (AMGN) Q2 2018 Earnings Results

Amgen Beats on EPS, Stock Up 0.52%

Amgen's earnings report showed a solid EPS beat, which contributed to a slight increase in the stock price. The positive surprise in EPS indicates better-than-expected profitability, reflecting strong performance in its key therapeutic areas. However, the lack of revenue data and guidance leaves some uncertainty for investors looking for future direction.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$3.83	N/A	+6.84%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Cautiously Optimistic

Overall, management expressed confidence in the company's strategic direction. They noted positive trends in product demand, although no specific guidance was provided.

Management highlighted strong performance in key therapeutic areas.

They emphasized ongoing commitment to innovation and pipeline development.

Amgen Beats on EPS, Stock Up 0.52%

Key numbers

Management commentary

Amgen Inc.

More earnings this week

Amgen Beats on EPS, Stock Up 0.52%

Key numbers

Management commentary